Leonardo Mina

Publication Activity (10 Years)

Years Active: 2022-2022
Publications (10 Years): 5

Top Topics

Metastatic Breast Cancer

Locally Advanced

Randomized Controlled Trial

Top Venues

Clinical cancer research : an official journal of the American Association for Cancer Research

This page only lists publications with an associated author ORCID identifier.

Publications

Ana López González, Sonia Del Barco Berrón, Isabel Grau, Maria Galan, Beatriz Castelo Fernández, Cortes Salgado Alfonso, Pedro Sánchez Rovira, Alejandro Martinez-Bueno, Xavier Gonzalez, Almudena García, Petra Gener, Leonardo Mina, Daniel Alcalá-López, Miguel Sampayo, Javier Cortes, José Manuel Pérez-Garcia, Antonio Llombart-Cussac, Elena López-Miranda
Challenging Endocrine Sensitivity of Hormone Receptor-Positive/HER2-Negative Advanced Breast Cancer with the Combination of Eribulin and Endocrine Therapy: The REVERT Study. Cancers 14 (23) (2022)
Joan Albanell, José Manuel Peréz-García, Juan Miguel Gil-Gil, Curigliano Giuseppe, Manuel Ruiz Borrego, Laura Comerma, Joan Gibert, Meritxell Bellet-Ezquerra, Begoña Bermejo, Lourdes Calvo Martinez, Juan R De la Haba-Rodríguez, Enrique Espinosa, Alessandro Marco Marco Minisini, Vanesa Quiroga, Ana Santaballa Bertran, Leonardo Mina, Beatriz Bellosillo, Federico Rojo, Silvia Menéndez, Miguel Sampayo, Ramona Mihaela Popa, Andrea Malfettone, Javier Cortes, Antonio Llombart
Palbociclib Rechallenge for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial. Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Ana López González, Sonia Del Barco Berrón, Isabel Grau, Maria Galan, Beatriz Castelo Fernández, Cortes Salgado Alfonso, Pedro Sánchez Rovira, Alejandro Martinez-Bueno, Xavier Gonzalez, Almudena García, Petra Gener, Leonardo Mina, Daniel Alcalá-López, Miguel Sampayo, Javier Cortes, José Manuel Pérez-Garcia, Antonio Llombart-Cussac, Elena López-Miranda
Challenging Endocrine Sensitivity of Hormone Receptor-Positive/HER2-Negative Advanced Breast Cancer with the Combination of Eribulin and Endocrine Therapy: The REVERT Study. Cancers 14 (23) (2022)
Ana López González, Sonia Del Barco Berrón, Isabel Grau, Maria Galan, Beatriz Castelo Fernández, Cortes Salgado Alfonso, Pedro Sánchez Rovira, Alejandro Martinez-Bueno, Xavier Gonzalez, Almudena García, Petra Gener, Leonardo Mina, Daniel Alcalá-López, Miguel Sampayo, Javier Cortes, José Manuel Pérez-Garcia, Antonio Llombart-Cussac, Elena López-Miranda
Challenging Endocrine Sensitivity of Hormone Receptor-Positive/HER2-Negative Advanced Breast Cancer with the Combination of Eribulin and Endocrine Therapy: The REVERT Study. Cancers 14 (23) (2022)
Ana López González, Sonia Del Barco Berrón, Isabel Grau, Maria Galan, Beatriz Castelo Fernández, Cortes Salgado Alfonso, Pedro Sánchez Rovira, Alejandro Martinez-Bueno, Xavier Gonzalez, Almudena García, Petra Gener, Leonardo Mina, Daniel Alcalá-López, Miguel Sampayo, Javier Cortes, José Manuel Pérez-Garcia, Antonio Llombart-Cussac, Elena López-Miranda
Challenging Endocrine Sensitivity of Hormone Receptor-Positive/HER2-Negative Advanced Breast Cancer with the Combination of Eribulin and Endocrine Therapy: The REVERT Study. Cancers 14 (23) (2022)